5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting

  • PDF / 922,540 Bytes
  • 10 Pages / 595.276 x 790.866 pts Page_size
  • 33 Downloads / 184 Views

DOWNLOAD

REPORT


(2020) 21:72

RESEARCH ARTICLE

Open Access

5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study Reiko Matsui1, Kenichi Suzuki2,3, Tomomi Takiguchi2, Makoto Nishio4, Takeshi Koike1, Toshinobu Hayashi5,6, Takashi Seto7, Yuki Kogure8, Naoyuki Nogami9, Kimiko Fujiwara10, Hiroyasu Kaneda11,12, Tomohiko Harada13, Satoru Shimizu14, Masashi Kimura15, Hirotsugu Kenmotsu16, Mototsugu Shimokawa17 and Koichi Goto18*

Abstract Background: Of patients receiving moderate emetic risk chemotherapy (MEC), 30–90% experience chemotherapyinduced nausea and vomiting (CINV); however, the optimal antiemetic treatment remains controversial. Methods: In this multicenter, prospective, observational study of adults treated with MEC while receiving chemotherapy for various cancer types in Japan, the enrolled patients kept diaries documenting CINV. All participants received a 5-hydroxytryptamine-3 receptor antagonist and dexamethasone. (Continued on next page)

* Correspondence: [email protected] 18 Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa-shi, Chiba 277-8577, Japan Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Matsui et al. BMC Pharmacology and Toxicology

(2020) 21:72

Page 2 of 10

(Continued from previous page)

Results: Of the 400 patients enrolled from May 2013 to January 2015, 386 were eligible for evaluation. The median age was 64 (range, 26–84). The overall complete response (CR; no emetic events and no antiemetic measures) rate was 64%. The proportion of patients showing CR was low in the carboplatin (CBDCA)- and oxaliplatin-based chemotherapy groups, especially among women. We showed that the CR rates in men were high in the CBDCA (AUC5) + etoposide (ETP) (80%), capecitabine plus oxaliplatin (CAPOX) (78%), and CBDC